Year: 2026

$13.5 million financing, including $5 million from Corvus, supports ongoing generation of soquelitinib clinical data in China for atopic dermatitis and asthma, which are indications also in development by Corvus in the United States SOUTH SAN FRANCISCO, Calif., June 09, 2026 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced that it has participated in a new $13.5 million financing for Angel Pharmaceuticals Ltd. (Angel Pharma), the Company’s collaboration partner in China. Corvus co-founded Angel Pharma in 2020 to enable the clinical development and commercialization of its pipeline in China as well as the development of other novel drugs. Corvus is Angel Pharma’s largest shareholder and is investing $5 million in the current financing. The funding is anticipated...

Sprouts Listing Gives GURU Nationwide Access to the U.S. Natural Channel’s Most Engaged, Health-Conscious Shopper MONTRÉAL, June 09, 2026 (GLOBE NEWSWIRE) — GURU Organic Energy Corp. (TSX: GURU) (“GURU” or the “Company“), Canada’s leading organic energy drink brand1, today announced the nationwide availability of GURU Lite and its four Zero Sugar flavors at Sprouts Farmers Market locations across the United States, effective June 22, 2026.GURU’s energy drink lineup offers a unique combination that the category rarely delivers at scale: organic ingredients, zero sugar, no sucralose, and no aspartame; a clean-label standard that speaks directly to the Sprouts shopper. The listing marks a significant milestone in GURU’s U.S. growth strategy, bringing its clean-label, organic lineup...

Monthly CPP Reaches Record Level TORONTO, June 09, 2026 (GLOBE NEWSWIRE) — (TSX: CGX) – Cineplex, Canada’s leading entertainment and media company, reported box office revenues of $60.5 million for May 2026, delivering its highest May box office since 2019.Period 2025 Box Office (i) 2026 Box Office (i) 2026 as a Percentage of 2025April $51,375 $60,012 117%May $55,331 $60,450 109%Q2 to date $106,706 $120,462 113%(i) Amounts are in thousands of dollars. Cineplex’s May performance was driven by a compelling and diverse film slate, resulting in strong audience engagement, with notable strength among younger moviegoers. Top performing films reflected a balance of franchise and original content, and included The Devil Wears Prada 2, Michael (continuing from April), Obsession, Star Wars: The Mandalorian and Grogu, and...

Nes Ziona, June 09, 2026 (GLOBE NEWSWIRE) — QTREX Quantum Ltd. (Nasdaq: QTEX) (“QTREX” or the “Company”), a company focused on advancing Additively Manufactured Electronics (“AME”) for quantum computing infrastructure, today announced that the Israel Innovation Authority (“IIA”) has awarded the Company an approximately $1 million grant to support the development of a purpose-built dielectric material engineered for high-density, low-loss RF signal routing in scalable superconducting quantum computing systems. QTREX’s program targets one of the core scaling constraints in superconducting quantum computing: the growing need to move more RF and microwave signals through cryogenic environments with lower loss, higher density and fewer assembly points. QTREX is developing the material as a native layer within...

Châtillon, France, June 9, 2026 DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced that company management will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, in Miami, FL. Mr. Daniel Tassé, CEO, will not be available for the previously scheduled fireside chat due to an unavoidable disruption of planned travel to the conference. About DBV TechnologiesDBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently...

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) — Lahontan Gold Corp. (TSXV:LG, OTCQB:LGCXF, FSE:Y2F) (the “Company” or “Lahontan“) is pleased to announce the first drill results from its 2026 drilling program at the Santa Fe Mine Project. The drill results reported herein cover four diamond core drill holes totalling 953 metres that were designed to acquire geotechnical data related to mine permitting that nonetheless intercepted significant gold mineralization. Five additional reverse-circulation (“RC”) drill holes, totalling 1,530 metres, have discovered a previously unrecognized zone of gold mineralization located west of the Slab open pit (“Slab West”) that remains open in all directions. Significant results are summarized below:Calvada: Drill hole CAL26-02C, originally designed to gather geotechnical data...

Company Outlines Path Toward Integrated Testing and Independent Validation SOUTHLAKE, Texas, June 09, 2026 (GLOBE NEWSWIRE) — American Fusion Inc. (OTC: AMFN) (“American Fusion” or the “Company”), a company developing advanced fusion energy technologies, including its Texatron™ Fusion Engine™ platform, is pleased to provide shareholders with an update regarding the development and testing schedule for its 5MW Pre-Production Texatron™ Fusion Engine™. The Company continues to advance development activities associated with its 5MW pre-production platform and believes it is approaching a pivotal stage in the evolution of the Texatron™ Fusion Engine™ program. The upcoming testing campaign is intended to evaluate key system performance metrics, validate subsystem integration, and generate independent...

Partnership supports reimbursement strategy and U.S. commercial expansion for Aclarion’s AI-driven platform for chronic low back pain. Program aims to follow successful reimbursement wins in the UK that are translating into sustained scan volume growth in step with reduced market access barriers BROOMFIELD, Colo., June 09, 2026 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a Market Access Program in partnership with PRIA Healthcare. This initiative represents a significant step in Aclarion’s strategy to advance Nociscan®, the company’s proprietary AI-driven platform...

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) — Fredonia Mining Inc. (“Fredonia” or the “Company”) (TSXV: FRED) is pleased to provide an update on recent corporate and technical developments as it continues to advance its flagship El Dorado Monserrat (“EDM”) Project in Santa Cruz Province, Argentina. Over the past several months, Fredonia has continued to execute key initiatives aimed at enhancing the value and long-term development potential of the EDM Project. Progress has been made across several areas, including the ongoing Preliminary Economic Assessment (“PEA”), strategic district consolidation efforts, and the evaluation of opportunities within the broader project area. “Our team has remained focused on creating long-term value through disciplined technical work, strategic land acquisitions and ongoing project evaluation. During...

TORONTO, June 09, 2026 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that senior management will deliver a corporate presentation at the Sidoti Small Cap Conference on June 18, 2026, at 9:15 am ET. Interested parties can access the live presentation through the following link: Access Live Presentation The Company will also participate in one-on-one meetings at the virtual event on June 17th and June 18th, 2026. During the corporate presentation, NetraMark Chief Executive Officer, George Achilleos, intends to discuss the Company’s commercial, clinical, and regulatory progress with respect to NetraAI,...